Once those prices are set, most large government programs that cover prescription drugs pay prices that are tied to ...
Preventing unnecessary exposure in diagnostic nuclear medicine ...
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...
The U.S. Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex ...
Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback